Hye Yung Yum

Hye Yung Yum

Auto-generated profile, based on publicly available information

Hye Yung Yum

Department of Pediatrics, Seoul Medical Center, Seoul, Korea

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Journal of Korean Medical Science
Verified
Journal Article
Open access
YJYou Hoon Jeon
You Hoon Jeon
SLSooyoung Lee
Sooyoung Lee
KAKangmo Ahn
Kangmo Ahn
SLSo-Yeon Lee
So-Yeon Lee
KKKyung Won Kim
Kyung Won Kim
RDRespiratory Disease
Respiratory Disease
Jeon YH, et al. J Korean Med Sci. 2019 Mar;34(13):e106. https://doi.org/10.3346/jkms.2019.34.e106

1 January 2013 in Allergy, Asthma & Immunology Research
Verified
Journal Article
Open access
PDF file
SLSeon Ah Lee
Seon Ah Lee
SHSoyoung Hong
Soyoung Hong
HKHyun Jung Kim
Hyun Jung Kim
SLSoo Hyung Lee
Soo Hyung Lee
HYHye Yung Yum
Hye Yung Yum
Lee SA, et al. Allergy Asthma Immunol Res. 2013 Jul;5(4):207-210. https://doi.org/10.4168/aair.2013.5.4.207

1 January 2022 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
YJYou Hoon Jeon
You Hoon Jeon
KAKangmo Ahn
Kangmo Ahn
JKJihyun Kim
Jihyun Kim
MSMeeyong Shin
Meeyong Shin
SHSoo-Jong Hong
Soo-Jong Hong
RDRespiratory Disease
Respiratory Disease
Jeon YH, et al. J Korean Med Sci. 2022 Jan;37(4):e30. https://doi.org/10.3346/jkms.2022.37.e30

1 January 2018 in Allergy, Asthma & Immunology Research
Verified
Journal Article
Open access
HYHye Yung Yum
Hye Yung Yum
HKHyun Jung Kim
Hyun Jung Kim
WKWoo Kyung Kim
Woo Kyung Kim
SLSo-Yeon Lee
So-Yeon Lee
KLKapsok Li
Kapsok Li
TDThe KAAACI Work Group on Severe/Recalcitrant Atopic Dermatitis
The KAAACI Work Group on Severe/Recalcitrant Atopic Dermatitis
There is an unmet need for the treatment of moderate-to-severe atopic dermatitis (AD), leading to variation in management strategies. To investigate distinct features and treatment modalities according to physicians' specialties, we collected data on the current treatment approach to moderate-to-severe AD among allergists, pediatric allergists and dermatologists in Korea. This questionnaire-based study was administered to physicians from the Korean Academy of Asthma, Allergy and Clinical Immunology (KAAACI), Korean Academy of Pediatric Allergy and Respiratory Disease (KAPARD), and Korean Atopic Dermatitis Association (KADA). A total of 93 physicians participated in the study; 64.5% were pediatric allergists and 31.2% were dermatologists. The major patient age groups were "less than 5 years" for 100% of pediatric allergists and "6-12 years old" for 38% of dermatologists. The proportion of patients with moderate-to-severe AD was higher for dermatologists and allergists compared to pediatric allergists. Physicians agreed on the necessity of education including demonstration of basic skin care and application of topical therapies (88.2%), nutritional consultation (83.9%) and psychological counseling (75.3%). However, less than half were able to educate and counsel their patients in real practice. There were noticeable differences in first-line treatment among physician groups. For pediatric allergists, the order of preferred systemic treatment was wet wrap therapy, systemic corticosteroids and oral cyclosporin. Dermatologists ranked cyclosporin, phototherapy, and systemic corticosteroids as first-line treatment regimens. Major reported barriers to proper management were steroid phobia, unproven complementary and alternative medicine, lack of education, and the unreasonable insurance system. Our findings suggest there are distinct differences in moderate-to-severe AD treatment according to physicians' specialties. Medical policy changes along with governmental supports are required in order to implement the ideal approach in real practice. For moderate-to-severe AD, a consensus on the approach to optimal management should be reached for the best outcomes, based on further randomized controlled trials.

1 January 2019 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
MLMin Kyung Lee
Min Kyung Lee
JSJu-Hee Seo
Ju-Hee Seo
HCHoward Chu
Howard Chu
HKHyun Jung Kim
Hyun Jung Kim
YJYong Hyun Jang
Yong Hyun Jang
CPChang Ook Park
Chang Ook Park
Lee MK, et al. Yonsei Med J. 2019 Jul;60(7):694-699. https://doi.org/10.3349/ymj.2019.60.7.694

22 October 2009 in International Archives of Allergy and Immunology
Verified
Journal Article
Open access
PDF file
DSDae Jin Song
Dae Jin Song
MMMyung Goo Min
Myung Goo Min
MMMarina Miller
Marina Miller
JCJae Youn Cho
Jae Youn Cho
HYHye Yung Yum
Hye Yung Yum
DBDavid H. Broide
David H. Broide
Background: As passive environmental tobacco smoke (ETS) exposure in nonsmokers can increase both asthma symptoms and the frequency of asthma exacerbations, we utilized a mouse model, in which ovalbumin (OVA) + ETS induce significantly increased levels of eosinophilic airway inflammation and remodeling compared to either stimulus alone, to determine whether a Toll-like receptor-9 (TLR-9) agonist could reduce levels of airway inflammation, airway remodeling and airway hyperreactivity (AHR). Methods: Mice treated with or without a TLR-9 agonist were sensitized to OVA and challenged with OVA + ETS for 1 month. AHR to methacholine was assessed in intubated and ventilated mice. Lung Th2 cytokines and TGF-β1 were measured by ELISA. Lungs were processed for histology and immunohistology to quantify eosinophils, mucus, peribronchial fibrosis and smooth muscle changes using image analysis. Results: Administration of a TLR-9 agonist to mice coexposed to chronic ETS and chronic OVA allergen significantly reduced levels of eosinophilic airway inflammation, mucus production, peribronchial fibrosis, the thickness of the peribronchial smooth muscle layer, and AHR. The reduced airway remodeling in mice treated with the TLR-9 agonist was associated with significantly reduced numbers of peribronchial MBP+ and peribronchial TGF-β1+ cells, and with significantly reduced levels of lung Th2 cytokines [interleukin-5 and interleukin-13] and TGF-β1. Conclusion: These studies demonstrate that TLR-9-based therapies inhibit airway inflammation, remodeling and AHR in mice coexposed to ETS and allergen who exhibit enhanced airway inflammation and remodeling.